Filtered By:
Drug: Famotidine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 7 results found since Jan 2013.
Fast Heartburn Relief Without Deadly Drugs
Since gastroesophageal reflux disease (GERD) was first identified in the early 1930s, the number of people experiencing heartburn has increased substantially.
In fact, one study shows that in just 10 years, the number of people experiencing:1
Any GERD symptoms increased by 30%
Symptoms at least once a week increased by 47%
Severe GERD increased by 24%
While these numbers are concerning, I’ll admit they’re not surprising considering the typical American diet.
Our nutrition-less, grain-based diet of carbohydrates and starches has wrecked our health and made our bodies behave in ways nature never intended.
This has led ...
Source: Al Sears, MD Natural Remedies - August 28, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Heart Health Natural Cures Nutrition Source Type: news
This Popular Kind Of Heartburn Medicine Can Increase Stroke Risk
This study further questions the cardiovascular safety of these drugs,” Sehested said.
Although the study found an association between PPIs and stroke risk, it does not prove cause and effect. More studies are needed, and doctors should consider if and for how long patients should take these drugs, the researchers said. [7 Bizarre Drug Side Effects]
PPIs are not the only medicines available to treat heartburn. The researchers noted that another type of heartburn medication, called a histamine H2 antagonist, was found to have no association with stroke risk in the study. Histamine H2 antagonists include famotidine (Pe...
Source: Science - The Huffington Post - November 21, 2016 Category: Science Source Type: news
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration
Publication date: September 2016 Source:Annals of Emergency Medicine, Volume 68, Issue 3 Author(s): Lesley Pahs, Chris Droege, Hilary Kneale, Arthur Pancioli Orolingual angioedema is a rare adverse effect of tissue plasminogen activator (tPA), with an incidence of 1% to 5%. There are currently no published reports describing resolution of tPA-induced orolingual angioedema with complement inhibitor therapy. A 72-year-old man receiving home angiotensin-converting enzyme inhibitor therapy presented to the emergency department with newly developed orolingual angioedema after treatment with tPA for acute ischemic stroke. Thera...
Source: Annals of Emergency Medicine - August 24, 2016 Category: Emergency Medicine Source Type: research
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration
Publication date: Available online 10 May 2016 Source:Annals of Emergency Medicine Author(s): Lesley Pahs, Chris Droege, Hilary Kneale, Arthur Pancioli Orolingual angioedema is a rare adverse effect of tissue plasminogen activator (tPA), with an incidence of 1% to 5%. There are currently no published reports describing resolution of tPA-induced orolingual angioedema with complement inhibitor therapy. A 72-year-old man receiving home angiotensin-converting enzyme inhibitor therapy presented to the emergency department with newly developed orolingual angioedema after treatment with tPA for acute ischemic stroke. Therap...
Source: Annals of Emergency Medicine - May 9, 2016 Category: Emergency Medicine Source Type: research
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
CONCLUSION: Famotidine does not affect the pharmacokinetics of apixaban, consistent with the physicochemical properties of apixaban (lack of an ionizable group and pH-independent solubility). Apixaban pharmacokinetics would not be affected by an increase in gastrointestinal pH due to underlying conditions (eg, achlorhydria), or by gastrointestinal pH-mediated effects of other histamine H2-receptor antagonists, antacids, or proton pump inhibitors. Given that famotidine is also an inhibitor of the human organic cation transporter (hOCT), these results indicate that apixaban pharmacokinetics are not influenced by hOCT uptake ...
Source: Clinical Pharmacology: Advances and Applications - November 29, 2015 Category: Allergy & Immunology Tags: Clin Pharmacol Source Type: research
Daily low-dose aspirin can prevent heart attack and stroke but is often misused
Aspirin is often hailed as a wonder drug, thanks to its ability to help stave off heart attacks and clot-caused strokes. But fewer than half of people who could benefit from a daily low-dose aspirin take it, while many others take it when they shouldn't, reports the January 2014 Harvard Heart Letter.
If you don't have heart disease, but do have high blood pressure, diabetes, or other risk factors for heart disease, don't automatically assume that taking aspirin every day is a good idea. "A lot of people take aspirin who really shouldn't," says Dr. Christopher Cannon, a cardiologist at Brigham and Women's Hospital and profe...
Source: New Harvard Health Information - December 20, 2013 Category: Consumer Health News Source Type: news
Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone
Commentary on: Laine L, Kivitz AJ, Bello AE, et al.. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379–86. Context Non-steroidal anti-inflammatory drugs (NSAID) are widely prescribed worldwide. However, NSAID use frequently accompanies gastrointestinal (GI) injury including complications such as bleeding and perforation. Therefore co-therapy with gastroprotective drugs especially for those at risk has been advocated in current guidelines1 in which proton-pump inhibitors (PPI) and misoprostol ...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: Sugano, K. Tags: Clinical trials (epidemiology), Small intestine, Stomach and duodenum, Drugs: cardiovascular system, Stroke, Drugs: musculoskeletal and joint diseases Therapeutics Source Type: research
